Get the Stockscreener App
109.09
1.60%
1.72
After Hours:
109.25
0.16
+0.15%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $109.09, with a volume of 7.93M.
It is up +1.60% in the last 24 hours and up +5.74% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$107.37
Open:
$108.3
24h Volume:
7.93M
Relative Volume:
0.86
Market Cap:
$135.70B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
22.97
EPS:
4.75
Net Cash Flow:
$9.84B
1W Performance:
-0.02%
1M Performance:
+5.74%
6M Performance:
+18.05%
1Y Performance:
+66.09%
1-Day Range:
$108.04
$109.55
1-Week Range:
$105.58
$109.55
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
109.09 | 135.73B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
725.22 | 670.62B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.25 | 369.72B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.72 | 326.52B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
113.21 | 221.76B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
70.44 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance
Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN
Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter
Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey
Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus
After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma
Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus
Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com
Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha
Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus
ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire
Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma
Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com
HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com
Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus
Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech
Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 10 - 3BL Media
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com
Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks
Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace
Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus
Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com
Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are - simplywall.st
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):